SCHEMBL6885111

SCHEMBL6885111

O=C(NS(=O)(=O)C1CC1)C1CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.37
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
POLB P06746 3/20 0.34
KMT2A Q03164 2/20 0.34
HPGD P15428 3/20 0.33
HTT P42858 2/20 0.33
LMNA P02545 2/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
USP2 O75604 1/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
JAK2 O60674 1/20 0.32
GAK O14976 1/20 0.32
STK16 O75716 1/20 0.32
AAK1 Q2M2I8 1/20 0.32
BMP2K Q9NSY1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12770192 0.91 EPHX2 (0.42) EPHX2HDAC8HDAC6POLBHPGD
SCHEMBL22169636 0.89 HDAC8 (0.45) EPHX2HDAC8HDAC6POLBHPGD
SCHEMBL22169725 0.85 HDAC8 (0.50) EPHX2HDAC8HDAC6HPGDHTT
SCHEMBL22169769 0.83 HDAC8 (0.48) EPHX2HDAC8HDAC6HPGDHTT
SCHEMBL30466711 0.78 TSHR (0.36) POLBKMT2ALMNASMN1; SMN2
SCHEMBL3050772 0.75 SCN9A (0.33) HDAC4
SCHEMBL6382335 0.73 SCN9A (0.31)
SCHEMBL13561 0.73 SCN9A (0.33) SMN1; SMN2
SCHEMBL4110765 0.73 POLB (0.36) HDAC8HDAC6POLBKMT2AHPGD
SCHEMBL27704919 0.73 TDP1 (0.34) KMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265606-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-10-21 EP disclosed
EP-1951743-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-03-19 EP disclosed
WO-2011002808-A1 HCV PROTEASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-01-06 WO disclosed
WO-2010045266-A1 THERAPEUTIC ANTIVIRAL PEPTIDES INTERMUNE, INC. (US) 2010-04-22 WO disclosed
WO-2009082701-A1 HCV PROTEASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2009-07-02 WO disclosed
WO-2008064061-A1 MACROCYCLIC PEPTIDES AS HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-29 WO disclosed
WO-2007044933-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-19 WO disclosed
WO-2007015824-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2007-02-08 WO disclosed
WO-2006122188-A2 TRIPEPTIDES AS HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-16 WO disclosed
WO-2006086381-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-17 WO disclosed
WO-2005095403-A2 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2005-10-13 WO disclosed
WO-2005037214-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION INTERMUNE, INC. (US) 2005-04-28 WO disclosed
WO-2004094452-A2 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-04 WO disclosed